119. Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Hyman DM(1), Piha-Paul SA(2), Won H(1), Rodon J(3), Saura C(3), Shapiro GI(4),Juric D(5), Quinn DI(6), Moreno V(7), Doger B(7), Mayer IA(8), Boni V(9), CalvoE(9), Loi S(10), Lockhart AC(11), Erinjeri JP(1), Scaltriti M(1), Ulaner GA(1),Patel J(1), Tang J(1), Beer H(1), Selcuklu SD(1), Hanrahan AJ(1), Bouvier N(1),Melcer M(1), Murali R(1), Schram AM(1), Smyth LM(1), Jhaveri K(1), Li BT(1),Drilon A(1), Harding JJ(1), Iyer G(1), Taylor BS(1), Berger MF(1), Cutler REJr(12), Xu F(12), Butturini A(12), Eli LD(12), Mann G(12), Farrell C(12), Lalani AS(12), Bryce RP(12), Arteaga CL(8), Meric-Bernstam F(2), Baselga J(1), SolitDB(1).Author information: (1)Memorial Sloan Kettering Cancer Center, New York, New York, USA.(2)University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.(3)Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO),Barcelona, Spain.(4)Dana-Faber Cancer Institute, Boston, Massachusetts, USA.(5)Massachusetts Hospital Cancer Center, Boston, Massachusetts, USA.(6)USC Norris Comprehensive Cancer Center, Los Angeles, California, USA.(7)START Madrid Fundación Jímenez Díaz, Madrid, Spain.(8)Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.(9)START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.(10)Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.(11)Washington University in St. Louis School of Medicine, St Louis, Missouri,USA.(12)Puma Biotechnology Inc., Los Angeles, California, USA.Comment in    Nature. 2018 Feb 8;554(7691):173-175.Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively)are found in a wide range of cancers. Preclinical modelling suggests that asubset of these mutations lead to constitutive HER2 activation, but most remainbiologically uncharacterized. Here we define the biological and therapeuticimportance of known oncogenic HER2 and HER3 mutations and variants of unknownbiological importance by conducting a multi-histology, genomically selected,'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT;clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancersvaried as a function of both tumour type and mutant allele to a degree notpredicted by preclinical models, with the greatest activity seen in breast,cervical and biliary cancers and with tumours that contain kinase domain missensemutations. This study demonstrates how a molecularly driven clinical trial can beused to refine our biological understanding of both characterized and new genomicalterations with potential broad applicability for advancing the paradigm ofgenome-driven oncology.DOI: 10.1038/nature25475 PMCID: PMC5808581PMID: 29420467  [Indexed for MEDLINE]